SCHEMBL1640540

SCHEMBL1640540

C[C@H](NC(=O)c1cn(Cc2ccccc2)c(=O)cc1O)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
PDE10A Q9Y233 1/20 0.50
ITGA4 P13612 1/20 0.48
ITGB7 P26010 1/20 0.48
CNR2 P34972 6/20 0.47
CNR1 P21554 4/20 0.47
PTGER4 P35408 2/20 0.46
PTGDR Q13258 2/20 0.46
BRD4 O60885 2/20 0.46
MAPT P10636 1/20 0.46
BRD2 P25440 1/20 0.45
BRD3 Q15059 1/20 0.45
BRDT Q58F21 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
POLB P06746 1/20 0.45
CHIT1 Q13231 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1641721 1.00 KDM4E (0.53) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1641854 1.00 KDM4E (0.53) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1640552 0.93 PTGER4 (0.50) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1641827 0.89 BRD4 (0.57) BRD4MAPTBRD2BRD3BRDT
SCHEMBL1640573 0.83 BRD4 (0.65) ALDH1A1LMNAHPGDBRD4MAPT
SCHEMBL1642053 0.79 MAPT (0.59) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1640326 0.79 HSP90AA1 (0.58) KDM4EALDH1A1LMNAHPGDHSD17B10
SCHEMBL1642389 0.79 EGLN1 (0.48) ALDH1A1CNR2BRD4BRD2BRD3
SCHEMBL1640352 0.78 LMNA (0.55) KDM4EALDH1A1LMNABRD4MAPT
SCHEMBL1641959 0.78 KDM4E (0.48) KDM4EALDH1A1LMNAHPGDBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 KDM4E 521/4885ALDH1A1 227/4885LMNA 3462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.